Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Capital Gains: Zenefits cuts its own valuation to keep the lawyers out of the equation, Airbnb swells to $30 billion

J.P. Morgan is making a robotics play.

capital gains
capital gains
Todd Bernard / Recode

Once-mighty Zenefits has a new deal with its investors to keep them from suing the pants off Zenefits for the company’s major compliance scandal from earlier this year. More on that, and last week’s other big VC deals, below:

  • Airbnb is in the middle of a new funding round that would set the company’s value at $30 billion. Airbnb recently raised $1 billion in debt financing, and last year raised $1.5 billion at a $25.5 billion valuation.
  • Zenefits has altered the terms last year’s Series C funding round, giving investors (like Andreessen Horowitz, TPG and Insight Venture Partners) more equity in the company in exchange for no investor lawsuits related to its huge regulatory scandal earlier this year. The deal reduces Zenefits’ valuation from $4.5 billion to $2 billion (BuzzFeed News).
  • In May, the Wall Street Journal reported that self-driving car startup Zoox was in the middle of raising a round at a billion-dollar valuation. That round has now wrapped up, and it’s $200 million (Business Insider).
  • Thrive Market, a digital grocery that wants “to become the online equivalent of Costco for healthy foods,” raised $111 million in a round led by Invus, with participation from Greycroft Partners, E-Ventures, Cross Culture Ventures and others (New York Times).
  • Robotics startup Anki landed a $52.5 million funding round led by J.P. Morgan, with additional cash from Andreessen Horowitz, Index Ventures and Two Sigma (Fortune).
  • Google Capital is putting $46.4 million into Care.com, a publicly traded company that operates an online marketplace for caregivers. Google is getting preferred shares at $10.50 a pop, a 24 percent premium on Care.com’s share price before the deal was announced (New York Times).
  • Hiring software startup SmartRecruiters raised $30 million in a new funding round led by Insight Venture Partners (TechCrunch).
  • Arevo, a 3=D printing startup that focuses on enterprise customers like carmakers and medical equipment companies, raised $7 million in a new round led by Khosla Ventures (VentureBeat).

This article originally appeared on Recode.net.

See More:

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh